Elotuzumab for previously treated multiple myeloma (terminated appraisal)

  • Technology appraisal
  • TA434
  • Published: 
Download guidance (PDF)

Advice

NICE is unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma because no evidence submission was received from Bristol–Myers Squibb for the technology.

  • National Institute for Health and Care Excellence (NICE)